Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Sammons Cancer Center - Texas Oncology
mi
from
Dallas, TX
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Sammons Cancer Center - Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Novartis Investigative Site
mi
from
Charleroi,
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Novartis Investigative Site
mi
from
Charleroi,
Click here to add this to my saved trials
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
Status: Enrolling
Updated:  11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
Status: Enrolling
Updated: 11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Donald W. Hill, MD
mi
from
Casa Grande, AZ
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Donald W. Hill, MD
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Compassionate Cancer Care Medical Group, Inc
mi
from
Fountain Valley, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Compassionate Cancer Care Medical Group, Inc
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Desert Hospital Comprehensive Cancer Center
mi
from
Palm Springs, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Desert Hospital Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
American Institute of Research
mi
from
Whittier, CA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
American Institute of Research
mi
from
Whittier, CA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Georgetown University Medical Center
mi
from
Washington,
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Baptist Cancer Institute
mi
from
Jacksonville, FL
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Ocala Oncology Center
mi
from
Ocala, FL
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Brinz, Burroff, Gurtler, & Russo
mi
from
Metairie, LA
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Brinz, Burroff, Gurtler, & Russo
mi
from
Metairie, LA
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Cancer Specialists Of Oklahoma
mi
from
Oklahoma City, OK
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Cancer Specialists Of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Pharma Resource
mi
from
East Providence, RI
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Austin Cancer Centers
mi
from
Austin, TX
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Austin Cancer Centers
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated:  11/24/2015
Local Institution
mi
from
San Juan,
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Status: Enrolling
Updated: 11/24/2015
Local Institution
mi
from
San Juan,
Click here to add this to my saved trials
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver
Status: Enrolling
Updated:  11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver
Status: Enrolling
Updated: 11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated:  11/25/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated: 11/25/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated:  11/25/2015
Massachusetts General Hospital
mi
from
Boston, MA
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated: 11/25/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer
Status: Enrolling
Updated:  11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer
Status: Enrolling
Updated: 11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Status: Enrolling
Updated:  11/25/2015
Baltimore VA Medical Center
mi
from
Baltimore, MD
Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Status: Enrolling
Updated: 11/25/2015
Baltimore VA Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Stanford Comprehensive Cancer Center - Stanford
mi
from
Stanford, CA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Stanford Comprehensive Cancer Center - Stanford
mi
from
Stanford, CA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Boulder Community Hospital
mi
from
Boulder, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Porter Adventist Hospital
mi
from
Denver, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Joseph Hospital
mi
from
Denver, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Rose Medical Center
mi
from
Denver, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Swedish Medical Center
mi
from
Englewood, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
North Suburban Medical Center
mi
from
Thornton, CO
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
North Suburban Medical Center
mi
from
Thornton, CO
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Graham Hospital
mi
from
Canton, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Memorial Hospital
mi
from
Carthage, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Alexian Brothers Radiation Oncology
mi
from
Elk Grove Village, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Alexian Brothers Radiation Oncology
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Eureka Community Hospital
mi
from
Eureka, IL
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials